Schrödinger

79 articles with Schrödinger

• Schrödinger to Participate in Five Upcoming Investor Conferences

  11/22/2021

  Schrödinger today announced that management will participate virtually at the following investor conferences: 33rd Annual Piper Sandler Virtual Healthcare Conference.

• Schrödinger Reports Third Quarter 2021 Financial Results and Provides Company Update

  11/10/2021

  Schrödinger, Inc. today announced financial results for the third quarter ended September 30, 2021, and provided an update on the company.

• Schrödinger to Present at Jefferies London Healthcare Conference

  11/9/2021

  Schrödinger to Present at Jefferies London Healthcare Conference

• Schrödinger to Present New Preclinical Data From Its MALT1 Inhibitor Program at ASH 2021 Annual Meeting

  11/4/2021

  Schrödinger , Inc. today announced that new preclinical data on its small-molecule MALT1 inhibitors will be presented during a poster session at the American Society of Hematology (ASH) 63rd Annual Meeting taking place virtually and in Atlanta, Georgia, December 11-14, 2021.

• MD Anderson and Schrödinger Announce Strategic Research Collaboration to Accelerate Development of WEE1 Program

  10/7/2021

  The University of Texas MD Anderson Cancer Center and Schrödinger, Inc. today announced a two-year strategic research collaboration focused on accelerating and optimizing the development of Schrödinger’s WEE1 inhibitor program, an investigational therapeutic approach designed to target the WEE1 kinase.

• Schrödinger Reports Second Quarter 2021 Financial Results and Provides Company Update

  8/12/2021

  Schrödinger, Inc. today announced financial results for the quarter ended June 30, 2021, and provided an update on the company.

• Nimbus Therapeutics and Schrödinger Extend Longstanding Collaboration to Discover Novel Therapeutics for Select Targets

  8/12/2021

  Nimbus Therapeutics today announced the extension of its collaboration with Schrödinger, Inc. to discover and design small molecule therapeutics for a number of high-value targets using cutting-edge structure-based drug design approaches.

• Schrödinger Reported Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  7/16/2021

  Schrödinger, Inc. today reported that on July 15, 2021, the company granted non-statutory stock options to purchase an aggregate of 32,975 shares of the company’s common stock to 14 newly hired employees.

• Schrödinger to Present at Two Virtual Investor Conferences in July

  7/14/2021

  Schrödinger today announced that management will present at two investor conferences in July. On Tuesday, July 20, 2021, Schrödinger will provide a corporate overview at the Evercore ISI AI x Therapeutics Day. The presentation will take place virtually at 1:30 pm. ET.

• Schrödinger to Present at Two Investor Healthcare Conferences in June

  5/25/2021

  Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will provide a corporate overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021, at 3:00 p.m. ET.

• Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 19, 2021

  5/19/2021

  Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, reported that on May 15, 2021, the company granted non-statutory stock options to purchase an aggregate of 22,775 shares of the company’s common stock to 11 newly-hired employees.

• Schrödinger Reports First Quarter 2021 Financial Results and Provides Company Update

  5/11/2021

  First quarter total revenue of $32.1 million, up 23 percent year-over-year; Software revenue of $26.3 million, up 11 percent year-over-year

• Schrödinger to Present at the Bank of America Securities 2021 Virtual Healthcare Conference

  5/4/2021

  Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will provide a corporate overview at the Bank of America Securities 2021 Virtual Healthcare Conference. The presentation will take place virtually on Tuesday, May 11, 2021, at 3:30 pm. ET.

• Schrödinger to Host Conference Call to Discuss First Quarter 2021 Financial Results

  4/27/2021

  Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that it will host a conference call and webcast on Tuesday, May 11, 2021, at 8:30 a.m. ET to discuss first quarter 2021 financial results and provide a general business update.

• Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  4/16/2021

  Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today reported that on April 13, 2021, the company granted non-statutory stock options to purchase an aggregate of 7,450 shares of the company’s common stock to three newly-hired employees.

• Schrödinger Reports Preclinical Data on Novel, Selective CDC7 Inhibitors Presented at American Association for Cancer Research Annual Meeting

  4/12/2021

  – Data highlight continued progress across internal pipeline; Company continues to plan for multiple IND-enabling studies in 2021 and up to three IND applications in 2022 – – Schrödinger to provide an overview of CDC7, MALT1 and Wee1 programs during a webcast today at 10:00 a.m. ET –

• Schrödinger to Participate in BMO BioPharma Spotlight Series: Technology-Enabled Drug Discovery

  4/9/2021

  Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that Ramy Farid, Ph.D., chief executive officer at Schrödinger, will participate in a panel during the BMO BioPharma Spotlight Series: Technology-Enabled Drug Discovery. The panel will take place virtually on Friday, April 16, at 10:00 a.m. ET.

• Schrödinger to Host Webcast in Conjunction with Presentation of Preclinical Data for Its CDC7 Program at Virtual AACR Annual Meeting

  3/30/2021

  Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that it will host a webcast to review the preclinical data being presented from its CDC7 program during a virtual poster session at the upcoming American Association for Cancer Research (AACR) Annual Meeting.

• Schrödinger to Participate in Credit Suisse 2021 Healthcare Innovators Series: The Intersection of Drug Discovery, Drug Development and Artificial Intelligence

  3/17/2021

  Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that Ramy Farid, Ph.D., chief executive officer at Schrödinger, will participate in a panel during the Credit Suisse 2021 Healthcare Innovators Series:

• Schrödinger Reports Financial Results for the Fourth Quarter and Full Year 2020 and Provides Outlook for 2021

  3/4/2021

  Total revenue of $108.1 million in 2020, up 26 percent year-over-year Software revenue of $92.5 million in 2020, up 39 percent year-over-year Strong financial position enables continued investment in advancing the science underlying Schrödinger’s computational platform Internal pipeline progressing, with plans to submit investigational new drug applications in 2022 Conference call today, Thursday, March 4, at 8:30 a.m. ET